Search

Your search keyword '"Chuang, Min-Hsiang"' showing total 166 results
Start Over Author "Chuang, Min-Hsiang"
166 results on '"Chuang, Min-Hsiang"'

17. Malnutrition and the Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Multi-Institutional Population-Based Propensity Score-Matched Analysis

Author

Lee, Cheng-Ya, primary, Liang, Yung-Chun, additional, Hsu, Wan-Hsuan, additional, Tsai, Ya-Wen, additional, Liu, Ting-Hui, additional, Huang, Po-Yu, additional, Chuang, Min-Hsiang, additional, Hung, Kuo-Chuan, additional, Lee, Mei-Chuan, additional, Yu, Tsung, additional, Lai, Chih-Cheng, additional, Weng, Tzu-Chieh, additional, and Wu, Jheng-Yan, additional

Published
2024
Full Text
View/download PDF

18. Clinical effectiveness of nirmatrelvir plus ritonavir on the short‐ and long‐term outcome in high‐risk children with COVID‐19

Author

Wu, Jheng‐Yan, primary, Chen, Chia‐Chen, additional, Liu, Mei‐Yuan, additional, Hsu, Wan‐Hsuan, additional, Tsai, Ya‐Wen, additional, Liu, Ting‐Hui, additional, Pin‐Chien, Sung, additional, Huang, Po‐Yu, additional, Chuang, Min‐Hsiang, additional, Lee, Mei‐Chuan, additional, Hung, Kuo‐Chuan, additional, Yu, Tsung, additional, and Lai, Chih‐Cheng, additional

Published
2024
Full Text
View/download PDF

26. Nutritional deficiency anemia and post‐acute sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: A six‐month retrospective cohort analysis of 30 892 patients

Author

Wu, Jheng‐Yan, primary, Liu, Mei‐Yuan, additional, Hung, Kuo‐Chuan, additional, Hsu, Wan‐Hsuan, additional, Tsai, Ya‐Wen, additional, Liu, Ting‐Hui, additional, Huang, Po‐Yu, additional, Chuang, Min‐Hsiang, additional, Hsieh, Ya‐Ling, additional, Lai, Chi‐Cheng, additional, and Kuo, Yu‐Hsuan, additional

Published
2023
Full Text
View/download PDF

29. Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases.

Author

Liu, Ting-Hui, Wu, Jheng-Yan, Huang, Po-Yu, Hsu, Wan-Hsuan, Chuang, Min-Hsiang, Tsai, Ya-Wen, Lai, Chih-Cheng, and Huang, Chun-Yen

Abstract

This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV-r) in treating patients with COVID-19 who have preexisting cardiovascular diseases (CVDs). Patients with underlying CVDs and COVID-19 were included from the TriNetX network. We employed a 1:1 propensity score matching to create two comparable cohorts: patients receiving NMV-r and those not receiving NMV-r. The primary outcome was the composite outcome of all-cause hospitalization or death within 30 days. Propensity score matching yielded two matched cohorts of 10,847 patients each. The composite outcomes of all-cause hospitalization or death within 30 days were 2.2% (239 patients) in the NMV-r cohort and 4.7% (512 patients) in the control cohort, indicating reduced risk in the NMV-r cohort (hazard ratio [HR], 0.475; 95% confidence interval [CI], 0407–0.533). The NMV-r cohort exhibited lower risks of all-cause hospitalization (HR, 0.525; 95% CI, 0.449–0.615) and mortality (HR, 0.113; 95% CI, 0.052–0.246) compared with the control group. A similar trend was observed across most of the subgroups. Our findings indicate that NMV-r to treat COVID-19 could reduce all-cause hospitalization and death in patients with CVDs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Additional file 1 of Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials

Author

Wu, Jheng-Yan, Tsai, Ya-Wen, Hsu, Wan-Hsuan, Liu, Ting-Hui, Huang, Po-Yu, Chuang, Min-Hsiang, Liu, Mei-Yuan, and Lai, Chih-Cheng

Abstract

Additional file 1. Figure S1 Sensitivity analysis of primary outcome by excluding each study individually. Figure S2 Trial sequence analysis on 30-day all-cause mortality. Figure S3 Trial sequence analysis on the risk of mechanical ventilation. Figure S4 Trial sequence analysis on length of intensive care unit stay. Figure S5 Trial sequence analysis on the length of hospital stay. Figure S6 Trial sequence analysis on risk of gastrointestinal tract bleeding. Figure S7 Trial sequence analysis on risk of healthcare-associated infection. Figure S8 Trial sequence analysis on risk of acute kidney injury

Published
2023
Full Text
View/download PDF

46. General anesthesia but not conscious sedation improves functional outcome in patients receiving endovascular thrombectomy for acute ischemic stroke: A meta-analysis of randomized clinical trials and trial sequence analysis

Author

Lee, Chia-Wei, primary, Chang, Yang-Pei, additional, Huang, Yen-Ta, additional, Hsing, Chung-Hsi, additional, Pang, Yu-Li, additional, Chuang, Min-Hsiang, additional, Wu, Su-Zhen, additional, Sun, Cheuk-Kwan, additional, and Hung, Kuo-Chuan, additional

Published
2022
Full Text
View/download PDF

48. Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID‐19.

Author

Wu, Jheng‐Yan, Liu, Mei‐Yuan, Liu, Ting‐Hui, Chuang, Min‐Hsiang, Hsu, Wan‐Hsuan, Huang, Po‐Yu, Tsai, Ya‐Wen, Kuo, Chia‐Yin, Yeh, Chun‐Ting, and Lai, Chih‐Cheng

Subjects
COVID-19, PEOPLE with diabetes, TYPE 2 diabetes, PROPENSITY score matching, RITONAVIR
Abstract

The aim of this study was to investigate the clinical efficacy of a combination of nirmatrelvir and ritonavir (NMV‐r) for treating COVID‐19 in patients with diabetes mellitus (DM). This retrospective cohort study used the TriNetX research network to identify adult diabetic patients with COVID‐19 between January 1, 2020, and December 31, 2022. Propensity score matching was used to match patients who received NMV‐r (NMV‐r group) with those who did not receive NMV‐r (control group). The primary outcome was all‐cause hospitalization or death during the 30‐day follow‐up period. Two cohorts comprising 13 822 patients with balanced baseline characteristics were created using propensity score matching. During the follow‐up period, the NMV‐r group had a lower risk of all‐cause hospitalization or death than the control group (1.4% [n = 193] vs. 3.1% [n = 434]; hazard ratio [HR], 0.497; 95% confidence interval [CI], 0.420–0.589). Compared with the control group, the NMV‐r group also had a lower risk of all‐cause hospitalization (HR, 0.606; 95% CI, 0.508–0.723) and all‐cause mortality (HR, 0.076; 95% CI, 0.033–0.175). This lower risk was consistently observed in almost all subgroup analyses, which examined sex (male: 0.520 [0.401–0.675]; female: 0.586 [0.465–0.739]), age (age 18–64 years: 0.767 [0.601–0.980]; ≥65 years: 0.394 [0.308–0.505]), level of HbA1c (<7.5%: 0.490 [0.401–0.599]; ≥7.5%: 0.655 [0.441–0.972]), unvaccinated (0.466 [0.362–0.599]), type 1 DM (0.453 [0.286–0.718]) and type 2 DM (0.430 [0.361–0.511]). NMV‐r can help reduce the risk of all‐cause hospitalization or death in nonhospitalized patients with DM and COVID‐19. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results